These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 7570893)
1. Apparently successful treatment of two cases of post kala-azar dermal leishmaniasis with liposomal amphotericin B. Hashim FA; Khalil EA; Ismail A; el Hassan AM Trans R Soc Trop Med Hyg; 1995; 89(4):440. PubMed ID: 7570893 [No Abstract] [Full Text] [Related]
2. Post-kala-azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: treatment with liposomal amphotericin B. Roustan G; Jiménez JA; Gutiérrez-Solar B; Gallego JL; Alvar J; Patrón M Br J Dermatol; 1998 Mar; 138(3):526-8. PubMed ID: 9580814 [TBL] [Abstract][Full Text] [Related]
3. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277 [TBL] [Abstract][Full Text] [Related]
4. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Kumar D; Ramesh V; Verma S; Ramam M; Salotra P Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997 [No Abstract] [Full Text] [Related]
5. A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis. Pandey K; Pal B; Siddiqui NA; Lal CS; Ali V; Bimal S; Kumar A; Verma N; Das VNR; Singh SK; Topno RK; Das P Indian J Dermatol Venereol Leprol; 2021; 87(1):34-41. PubMed ID: 33580944 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744 [TBL] [Abstract][Full Text] [Related]
7. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine. Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510 [TBL] [Abstract][Full Text] [Related]
8. Atypical presentation of post-kala-azar dermal leishmaniasis. Islam QT; Basher A Lancet Infect Dis; 2017 Nov; 17(11):1218. PubMed ID: 29115271 [No Abstract] [Full Text] [Related]
9. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India. Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204 [TBL] [Abstract][Full Text] [Related]
10. Treatment of post-kala-azar dermal leishmaniasis. Ramesh V Int J Dermatol; 1994 Mar; 33(3):153-6. PubMed ID: 8169009 [No Abstract] [Full Text] [Related]
11. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal. Karki P; Koirala S; Parija SC; Sethi M; Das ML Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510 [TBL] [Abstract][Full Text] [Related]
12. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report. Ramesh V; Avishek K; Sharma V; Salotra P Acta Derm Venereol; 2014 Mar; 94(2):242-3. PubMed ID: 23995012 [No Abstract] [Full Text] [Related]
13. Post-kala-azar dermal leishmaniasis (PKDL), HIV and pulmonary tuberculosis. Das VN; Pandey K; Verma N; Bimal S; Lal CS; Singh D; Das P Natl Med J India; 2010; 23(2):88-9. PubMed ID: 20925205 [TBL] [Abstract][Full Text] [Related]
14. Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report. Lindoso JAL; Moreira CHV; Celeste BJ; Oyafuso LKM; Folegatti PM; Zijlstra EE Rev Soc Bras Med Trop; 2018; 51(1):105-107. PubMed ID: 29513829 [TBL] [Abstract][Full Text] [Related]
15. Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review. Trindade MA; Silva LL; Braz LM; Amato VS; Naafs B; Sotto MN BMC Infect Dis; 2015 Nov; 15():543. PubMed ID: 26592919 [TBL] [Abstract][Full Text] [Related]
16. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]